AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18240991 — intervention group
Group type: EXPERIMENTAL
Intervention: TalkToYourDoc (TTYD) website module
Number of subjects: 288
Study 18240991 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 288
Study 16492585 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 400 mg orally every 6 hours for 10 days
Number of subjects: 80
Study 16492585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12580656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg every 8 hours for 48 hours
Number of subjects: 19
Study 12580656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10933096 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 39
Study 9354005 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated maternal serum beta-hCG levels
Number of subjects: 105
Study 9354005 — intervention group
Group type: COMPARATOR
Intervention: Normotensive mothers
Number of subjects: 105
Study 9354005 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuric pregnancy induced hypertension
Number of subjects: 105
Study 9354005 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pregnancy hypertension
Number of subjects: 105
Study 8473263 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-word error correction (teacher stated the complete word and the student repeated it)
Number of subjects: 5
Study 8473263 — intervention group
Group type: COMPARATOR
Intervention: Phonetic-prompt error correction (teacher provided phonetic prompts)
Number of subjects: 5
Study 3899020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma 10 ml/kg on admission and at 24 hours of age
Number of subjects: 73
Study 3899020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 73
Study 31557603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh air ventilation system with high efficiency particulate air filter (FAVS-HEPA)
Number of subjects: 43
Study 28719366 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based anger management program for 8 weeks
Number of subjects: 140
Study 28719366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study 25804970 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter stride length (±25% of desired stride length)
Number of subjects: 19
Study 25804970 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer stride length (±25% of desired stride length)
Number of subjects: 19
Study 22836600 — intervention group
Group type: EXPERIMENTAL
Intervention: Single training workload (3 series of 6 throws with a 3‐kg medicine ball)
Number of subjects: 40
Study 22836600 — intervention group
Group type: EXPERIMENTAL
Intervention: Double training workload (6 series of 6 throws with a 3‐kg medicine ball)
Number of subjects: 40
Study 22836600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 40
Study 22836600 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with 3-kg medicine balls
Number of subjects: 40
Study 21818029 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief in‐hospital psychoeducational violence intervention (BVI) alone
Number of subjects: 75
Study 21818029 — intervention group
Group type: EXPERIMENTAL
Intervention: BVI + Community Case Management Services (CCMS)
Number of subjects: 75
Study 21818029 — intervention group
Group type: COMPARATOR
Intervention: Control group (BVI alone)
Number of subjects: 75
Study 19702704 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Acri.Smart 36A)
Number of subjects: 31
Study 19702704 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOL (Rayner Superflex 620H)
Number of subjects: 31
Study 16415410 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifen (30 mg daily for 3 menstrual cycles)
Number of subjects: 195
Study 16415410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 15322598 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs alone
Number of subjects: 78
Study 15322598 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI and digoxin
Number of subjects: 78
Study 15322598 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 78
Study 15322598 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy excluding ACEIs
Number of subjects: 78
Study 15322598 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI regimens
Number of subjects: 78
Study 15322598 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ACEI and digoxin
Number of subjects: 78
Study 11208939 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 8
Study 11208939 — intervention group
Group type: EXPERIMENTAL
Intervention: High Oleic Sunflower Oil (HOSO)
Number of subjects: 8
Study 11208939 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 8
Study 9290119 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg/day) for three months
Number of subjects: 37
Study 9290119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9290119 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg/day)
Number of subjects: 37
Study 8359618 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU of interferon tiw
Number of subjects: 65
Study 8359618 — intervention group
Group type: COMPARATOR
Intervention: 3 MU of interferon tiw
Number of subjects: 65
Study 3712182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers' perceptions of reasons for smoking (Reasons for Smoking Scale)
Number of subjects: 175
Study 3712182 — intervention group
Group type: COMPARATOR
Intervention: Criterion group of smokers (N = 81) who completed the Reasons scale
Number of subjects: 175
Study 31603268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dopamine (2 µg kg‐1 min‐1)
Number of subjects: 14
Study 31603268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline and D2‐receptor antagonist (20 mg oral metoclopramide)
Number of subjects: 14
Study 31603268 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline and placebo pill
Number of subjects: 14
Study 28748625 — intervention group
Group type: EXPERIMENTAL
Intervention: Full counseling (face-to-face cardiovascular risk assessment and personalized counseling on nutrition, physical activity, and smoking cessation in the ED, plus two telephone follow-up sessions)
Number of subjects: 140
Study 28748625 — intervention group
Group type: COMPARATOR
Intervention: Minimal counseling (brief instruction [<5 minutes] on benefits of modifying cardiovascular risk factors)
Number of subjects: 140
Study 28748625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms combined
Number of subjects: 140
Study 25061028 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle elongation (EME) session of 4 KHz interferential current, bipolar technique and AMF = 100 Hz, n = 40
Number of subjects: 120
Study 25061028 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT), n = 40
Number of subjects: 120
Study 25061028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, n = 40)
Number of subjects: 120
Study 23124781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified blood pressure control
Number of subjects: 84
Study 23124781 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood pressure control
Number of subjects: 84
Study 23124781 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition with improved BP control
Number of subjects: 84
Study 23124781 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 84
Study 22122912 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer Assisted Adherence Therapy (CAAT)
Number of subjects: 80
Study 22122912 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 80
Study 19369114 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-based survey
Number of subjects: 120
Study 19369114 — intervention group
Group type: COMPARATOR
Intervention: Paper-based survey
Number of subjects: 120
Study 16505207 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB; candesartan 8 mg/day, n=11 or valsartan 80 mg/day, n=22)
Number of subjects: 66
Study 16505207 — intervention group
Group type: COMPARATOR
Intervention: Trichlormethiazide (2 mg/day)
Number of subjects: 66
Study 14722001 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting technique
Number of subjects: 112
Study 14722001 — intervention group
Group type: COMPARATOR
Intervention: Traditional harvesting technique
Number of subjects: 112
Study 11763912 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil-containing dentifrice
Number of subjects: 0
Study 11763912 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 8875516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (group AA)
Number of subjects: 30
Study 8875516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (group ALAGLN)
Number of subjects: 30
Study 8875516 — intervention group
Group type: COMPARATOR
Intervention: Control group (glucose alone)
Number of subjects: 30
Study 1863724 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (desmopressin acetate) 0.3 microgram/kg infused intravenously over 5 seconds (group 1)
Number of subjects: 16
Study 1863724 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (desmopressin acetate) 0.3 microgram/kg administered over 5 minutes (group 2)
Number of subjects: 16
Study 1863724 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine infusion
Number of subjects: 16
Study 1863724 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (desmopressin acetate)
Number of subjects: 16
Study 6395275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1,000 mg once daily, with some patients receiving 500 mg)
Number of subjects: 100
Study 6395275 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (1,000 mg every 6 hours)
Number of subjects: 100
Study 30802720 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of spearmint extract (PSE)
Number of subjects: 142
Study 30802720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 142
Study 29996895 — intervention group
Group type: EXPERIMENTAL
Intervention: New Start intervention, delivered approximately 6 months post-stroke by trained staff (facilitators)
Number of subjects: 0
Study 25808690 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized collar (MC) implant at crestal bone level
Number of subjects: 33
Study 25808690 — intervention group
Group type: COMPARATOR
Intervention: Long collar (LC) implant 2.5 mm supracrestal
Number of subjects: 33
Study 25350960 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF)
Number of subjects: 708
Study 25350960 — intervention group
Group type: COMPARATOR
Intervention: atazanavir+ritonavir+emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF)
Number of subjects: 708
Study 22503786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised frusemide (40 mg, 4 ml)
Number of subjects: 32
Study 22503786 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (4 ml)
Number of subjects: 32
Study 19876062 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg before sleep)
Number of subjects: 60
Study 19876062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16896917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular hypertension patients
Number of subjects: 67
Study 16896917 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 15623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-spring attachment
Number of subjects: 100
Study 15623995 — intervention group
Group type: COMPARATOR
Intervention: Bar-clip attachment
Number of subjects: 100
Study 15623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both attachment mechanisms
Number of subjects: 100
Study 12118494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg droperidol
Number of subjects: 150
Study 12118494 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg metoclopramide
Number of subjects: 150
Study 12118494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous normal saline)
Number of subjects: 150
Study 12118494 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (droperidol, metoclopramide, placebo)
Number of subjects: 150
Study 10487566 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT plus radiosurgery
Number of subjects: 27
Study 10487566 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 27
Study 8711678 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine provocation testing (PD15)
Number of subjects: 495
Study 8711678 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak expiratory flow (PEF) monitoring
Number of subjects: 495
Study 8711678 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in one second (FEV1%)
Number of subjects: 495
Study 8711678 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (EXE)
Number of subjects: 495
Study 1885286 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 32
Study 1885286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with weight loss
Number of subjects: 32
Study 1885286 — intervention group
Group type: COMPARATOR
Intervention: Placebo with weight loss
Number of subjects: 32
Study 1885286 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 32
Study 1885286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7114936 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb-sparing resection plus adjuvant radiation therapy
Number of subjects: 43
Study 7114936 — intervention group
Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 43
Study 7114936 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 43
Study 7114936 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 43
Study 31075187 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 25 mg once daily
Number of subjects: 267
Study 31075187 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg once daily
Number of subjects: 267
Study 31075187 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg twice daily
Number of subjects: 267
Study 31075187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 267
Study 31075187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 31075187 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 267
Study 30075776 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care for patients with a substance use disorder
Number of subjects: 10
Study 30075776 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with patients and proxies
Number of subjects: 10
Study 30075776 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis of interviews
Number of subjects: 10
Study 30075776 — intervention group
Group type: EXPERIMENTAL
Intervention: SWOT analysis of group interview data
Number of subjects: 10
Study 26522674 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss and lifestyle intervention
Number of subjects: 200
Study 26522674 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 24643924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.2 mg) with 0.5% hyperbaric bupivacaine
Number of subjects: 30
Study 24643924 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.5% hyperbaric bupivacaine only)
Number of subjects: 30
Study 22616980 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy (EA)
Number of subjects: 143
Study 22616980 — intervention group
Group type: COMPARATOR
Intervention: Late amniotomy (LA)
Number of subjects: 143
Study 19085908 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IFN alfa-2b (PEG 2b) plus ribavirin (RBV)
Number of subjects: 182
Study 19085908 — intervention group
Group type: COMPARATOR
Intervention: PEG IFN alfa-2a (PEG 2a) plus ribavirin (RBV)
Number of subjects: 182
Study 17452537 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 572
Study 17452537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 572
Study 17452537 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 572
Study 15250647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention in a rehabilitation center
Number of subjects: 731
Study 15250647 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by occupational or primary health care services
Number of subjects: 731
Study 11096224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (6-12 mg/day)
Number of subjects: 0
Study 11096224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9419078 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 0
Study 9419078 — intervention group
Group type: COMPARATOR
Intervention: Upright position
Number of subjects: 0
Study 9419078 — intervention group
Group type: COMPARATOR
Intervention: Light condition
Number of subjects: 0
Study 9419078 — intervention group
Group type: COMPARATOR
Intervention: Dark condition
Number of subjects: 0
Study 8469820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (DBT1) at 5 micrograms/kg/min for 30 min
Number of subjects: 7
Study 8469820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DOP2) at a dose sufficient to induce a similar rise in MAP as DBT1
Number of subjects: 7
Study 8469820 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (NS1 and NS2)
Number of subjects: 7
Study 3081208 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 6.3 mmol/l (113.5 mg/100 ml)
Number of subjects: 16
Study 3081208 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 2.9 mmol/l (52.3 mg/100 ml)
Number of subjects: 16
Study 3081208 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 1.8 mmol/l (32.4 mg/100 ml)
Number of subjects: 16
Study 3081208 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 6.1 mmol/l (109.9 mg/100 ml) after intravenous glucose
Number of subjects: 16
Study 3081208 — intervention group
Group type: EXPERIMENTAL
Intervention: Period C (1.8 mmol/l)
Number of subjects: 16
Study 3081208 — intervention group
Group type: EXPERIMENTAL
Intervention: Period A (6.3 mmol/l) and Period B (2.9 mmol/l)
Number of subjects: 16
Study 3081208 — intervention group
Group type: EXPERIMENTAL
Intervention: Period D (6.1 mmol/l)
Number of subjects: 16
Study 3169372 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxofylline (200 mg intravenously over 15 min)
Number of subjects: 10
Study 3169372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3169372 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxofylline
Number of subjects: 10
Study 31859034 — intervention group
Group type: EXPERIMENTAL
Intervention: 11+ Kids warm-up programme
Number of subjects: 962
Study 31859034 — intervention group
Group type: COMPARATOR
Intervention: Standard warm-up programme (Control)
Number of subjects: 962
Study 31190496 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking intervention applied at specific auricular points (Shenmen, Shen, Wei, Gan, Pi, Pizhixia, E, Nie, Zhen), 3-5 minutes per point, 5 times a day for 1 week post-surgery
Number of subjects: 80
Study 31190496 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine preoperative guidance and visits
Number of subjects: 80
Study 31190496 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking intervention
Number of subjects: 80
Study 31190496 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 28497402 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of the primary tumor plus systemic chemotherapy after surgery
Number of subjects: 0
Study 28497402 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy alone
Number of subjects: 0
Study 26399752 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 143
Study 26399752 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 143
Study 26399752 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV (subgroup with surfactant therapy)
Number of subjects: 143
Study 26399752 — intervention group
Group type: COMPARATOR
Intervention: NCPAP (subgroup with surfactant therapy)
Number of subjects: 143
Study 23433347 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes specialist/educator consultation support (active for 2 months, passive for 10 months) and community retail pharmacist support (1-hour insulin-initiation session)
Number of subjects: 151
Study 23433347 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no additional support)
Number of subjects: 151
Study 21584948 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol (7.5 µg/dose)
Number of subjects: 0
Study 21584948 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol (15 µg/dose)
Number of subjects: 0
Study 21584948 — intervention group
Group type: COMPARATOR
Intervention: Levalbuterol (0.63 mg/dose)
Number of subjects: 0
Study 19084158 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR-Pa infection
Number of subjects: 28
Study 19084158 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer stay in ICU
Number of subjects: 28
Study 19084158 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized PAR-Pa infections
Number of subjects: 28
Study 16585472 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment for Substance Abuse in Severe and Persistent Mental Illness (BTSAS)
Number of subjects: 129
Study 16585472 — intervention group
Group type: COMPARATOR
Intervention: Supportive Treatment for Addiction Recovery (STAR)
Number of subjects: 129
Study 14689372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous angiotensin II infusion (0-512 ng/minute) during placebo therapy
Number of subjects: 10